Martin Hoyle


  • 1271 Citations
  • 22 h-Index
If you made any changes in Pure these will be visible here soon.

Personal profile


Prof Martin Hoyle is a Professor of Health Innovation and Evaluation at the Macquarie University Centre for the Health Economy (MUCHE).

He now leads a team of researchers in MUCHE that work on submissions for the Australian Medical Services Advisory Committee (MSAC) and critique pharmaceutical company submissions to the Australian Pharmaceutical Benefits Advisory Committee (PBAC).

Prof Hoyle has evaluated drugs in many clinical areas including various cancers (chronic lymphocytic leukaemia, chronic myeloid leukaemia, multiple myeloma, neuroendocrine tumours, colorectal cancer, gastro-intestinal stromal tumours, renal cell carcinoma, soft tissue sarcoma), chemotherapy-induced anaemia, multiple sclerosis, Alzheimer's disease. Other evaluations include vaccines for influenza, cochlear implants for hearing, diagnostic tests for Lynch Syndrome, tests for pre-term labour in women, influenza vaccines. He has defended Assessment Group reports at 34 UK NICE Appraisal Committee meetings and 2 ESC meetings in Australia.

He has published papers on HTA methodology, specifically on assumptions regarding appropriate patient cohorts to model, assumptions for future drug prices and a method to recreate and analyse individual patient data using only summary survival data.

He was the external examiner for the MSc in Health Economics and Decision Modelling, University of Sheffield, from 2016 to 2018, and was a panel member for the Research for Patient Benefit (RfPB) South West. He was also an advisor to NICE on implementation of the NICE Fast Track Appraisal (FTA) process, and an advisor to NICE on implementation of the "Adjusted TA" process.

Prior to joining the Centre, Martin was Director of PenTAG (Peninsula Technology Assessment Group) in the Medical School at the University of Exeter, where he performed health technology assessments for the National Institute for Health and Care Excellence (NICE), and the National Institute for Health Research (NIHR) in the United Kingdom. His undergraduate training was in Mathematics at the University of Cambridge.  This accounts for his interest in the mathematics and statistics of HTA.

Education/Academic qualification

Ecology, PhD

1 Sep 20001 Dec 2003

Ecology, MSc

31 Oct 199931 Aug 2001

Mathematical Statistics, Diploma

30 Sep 199231 Jul 1993

Mathematics, MA

1 Oct 198931 Jul 1992

Fingerprint Dive into the research topics where Martin Hoyle is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles
Cost-Benefit Analysis Medicine & Life Sciences
Quality-Adjusted Life Years Medicine & Life Sciences
Economic Models Medicine & Life Sciences
Costs and Cost Analysis Medicine & Life Sciences
National Institutes of Health (U.S.) Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
Technology Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2011 2017

Research Outputs 2004 2019

  • 1271 Citations
  • 22 h-Index
  • 47 Article
  • 19 Commissioned report
  • 1 Other report
  • 1 Review article

Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis

Tikhonova, I., Yang, H., Salmon, A., Bello, S., Peters, J., Robinson, S., Rezaei, M., Dodman, S., Coelho, H., Kharechko, A., Haigh, R., Jani, M., McDonald, T. J., Hoyle, M. & Logan, S., 2019, University of Exeter. 425 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation

Peninsula Technology Assessment Group (PenTAG), Varley-Campbell, J., Mújica-Mota, R., Coelho, H., Ocean, N., Barnish, M., Packman, D., Dodman, S., Cooper, C., Snowsill, T., Kay, T., Liversedge, N., Parr, M., Knight, L., Hyde, C., Shennan, A. & Hoyle, M., Mar 2019, In : Health Technology Assessment. 23, 13, p. 1-226 226 p.

Research output: Contribution to journalArticleResearch

Open Access
Premature Obstetric Labor
Quality-Adjusted Life Years
Cost-Benefit Analysis
Routine Diagnostic Tests

Benralizumab for treating severe asthma: A Single Technology Appraisal

Tikhonova, I., Long, L., Ocean, N., Barnish, M., Robinson, S., Nikram, E., Bello, S., Dodman, S., Halpin, D. & Hoyle, M., 2018, University of Exeter. 223 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Brigatinib for treating ALK-positive non-small-cell lung cancer after crizotinib [ID1328]: A Single Technology Appraisal

Griffin, E., Barnish, M., Packman, D., Coelho, H., Matthews, J., Dodman, S., Robinson, S., Dangoor, A., Dorey, N. & Hoyle, M., 2018, University of Exeter. 189 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Economic analysis of the first-line treatment with cetuximab or panitumumab for RAS wild-type metastatic colorectal cancer in England

Tikhonova, I. A., Huxley, N., Snowsill, T., Crathorne, L., Varley-Campbell, J., Napier, M. & Hoyle, M., Jul 2018, In : PharmacoEconomics. 36, 7, p. 837-851 15 p.

Research output: Contribution to journalArticleResearchpeer-review



Improving health and spending money wisely: evaluating medicines and vaccines for the Australian Government

Henry Cutler (Participant), Bonny Parkinson (Participant), Martin Hoyle (Participant), Mutsa Gumbie (Participant), Rachel Song (Participant), Andrew Partington (Participant), Varinder Jeet (Participant), Elizabeth Seil (Participant), Alicia Norman (Participant), Virginia Mumford (Participant), Sanjyot Vagholkar (Participant), Lisa Pont (Participant), Janaki Amin (Participant)

Impact: Quality of life impacts, Economic impacts, Public policy impacts